These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21413135)

  • 1. Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature.
    Dasari TW; Hennebry TA; Hanna EB; Saucedo JF
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):962-9. PubMed ID: 21413135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing long-term outcomes between drug-eluting and bare-metal stents in the treatment of cardiac allograft vasculopathy.
    Nfor T; Ansaarie I; Gupta A; Bajwa T; Allaqaband S
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):543-9. PubMed ID: 19405161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of percutaneous coronary intervention with bare-metal and drug-eluting stents for cardiac allograft vasculopathy.
    Lee MS; Kobashigawa J; Tobis J
    JACC Cardiovasc Interv; 2008 Dec; 1(6):710-5. PubMed ID: 19463388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug eluting stents for the treatment of bare metal in-stent restenosis: long-term outcomes in real world practice.
    Appleby CE; Khattar RS; Morgan K; Clarke B; Curzen N; Neyses L; Fath-Ordoubadi F
    EuroIntervention; 2011 Jan; 6(6):748-53. PubMed ID: 21205600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis.
    Singh IM; Filby SJ; El Sakr F; Gorodeski EZ; Lincoff AM; Ellis SG; Shishehbor MH
    Catheter Cardiovasc Interv; 2010 Aug; 76(2):257-62. PubMed ID: 20665874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting stent implantation for the treatment of cardiac transplant vasculopathy: the jury is still out.
    Belardi JA
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):970-1. PubMed ID: 21598349
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of drug-eluting balloon in patients with bare-metal or drug-eluting stent restenosis.
    Berta B; Jambrik Z; Kohar K; Szabo G; Ruzsa Z; Molnar L; Barczi G; Geller L; Becker D; Merkely B
    Hellenic J Cardiol; 2014; 55(5):369-77. PubMed ID: 25243435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty.
    Oh PC; Suh SY; Kang WC; Lee K; Han SH; Ahn T; Shin EK
    Korean J Intern Med; 2016 May; 31(3):501-6. PubMed ID: 26951915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting stents in patients with end-stage renal disease: meta-analysis and systematic review of the literature.
    Abdel-Latif A; Mukherjee D; Mesgarzadeh P; Ziada KM
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):942-8. PubMed ID: 20506492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study.
    Basavarajaiah S; Naganuma T; Latib A; Sticchi A; Ciconte G; Panoulas V; Chieffo A; Montorfano M; Carlino M; Colombo A
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):522-528. PubMed ID: 26715370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual?
    Wang FW; Uretsky BF; Freeman JL; Zhang D; Giordano SH; Goodwin JS
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):636-43. PubMed ID: 18360856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.